This clinical trial looks at genetic testing methods to find early signs of myeloid cancers and bone marrow problems. The goal is to discover genetic markers that can help identify patients at risk. Early detection may lead to quicker and more effective treatments. Researchers will study how these genetic features relate to the risk of developing these cancers and conditions.
The trial's ID is NCT02958462. This is not a drug or device study, and it falls outside the typical phases since it focuses on screening. The trial aims to include around 2,000 participants.
Who can join
Anyone 18 years or older can join this trial. It is open to men and women, including those with certain blood-related conditions. Family members of eligible patients can also participate. However, people under 18 cannot join.
Conditions
Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia, Bone Marrow Failure Syndrome, Clonal Cytopenia of Undetermined Significance, Clonal Hematopoiesis of Indeterminate Potential, Hematologic Neoplasms, Hematopoietic and Lymphatic System Neoplasm, Hereditary Neoplastic Syndrome, Idiopathic Cytopenia of Undetermined Significance, Idiopathic Dysplasia of Uncertain Significance, Low Risk Myelodysplastic Syndrome
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will undergo various tests, including blood samples and possibly a bone marrow biopsy. They may also have skin biopsies, hair follicle samples, and receive genetic counseling. Everyone in the trial will go through these assessments to help researchers understand the genetic information related to their health.
Where
This trial is running at 3 locations in the United States. All of them are currently recruiting.